Alexander Hein

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry

Manuel Hörner, Andreas Hartkopf, Nelson John, Philipp Ziegler et autres

de, us (code pays fourni par la source)

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial

Manuel Hörner, Lara Tretschock, Nelson John, Philipp Ziegler et autres

de, us (code pays fourni par la source)

Abstract PS3-08-14: Typer—A randomized controlled trial evaluating the effect of typology-based coaching on therapy management for patients with hr+/her2- early breast cancer under adjuvant ribociclib treatment

M. Welslau, Christine Zeder-Goess, Renate Haidinger, B. Welter et autres

de, us (code pays fourni par la source)

458eTiP Typer—A RCT evaluating the effect of typology-based coaching on therapy management in patients with HR+/HER2- early breast cancer under adjuvant ribociclib treatment

Manfred Welslau, Christine Zeder-Goess, Renate Haidinger, B. Welter et autres

de, us, pk (code pays fourni par la source)

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

Laura L. Michel, Philipp Kreis, Andreas D. Hartkopf, Markus Wallwiener et autres

de, us (code pays fourni par la source)

Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2 ‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

Milena Beierlein, Lothar Häberle, Naiba Nabieva, Nicolaì Maass et autres

de, us, ee, ch (code pays fourni par la source)

Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

Volkmar Müller, Manuel Hörner, Marc Thill, Maggie Banys‐Paluchowski et autres

de, us (code pays fourni par la source)

Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer

Christina Barbara Walter, Andreas D. Hartkopf, Alexander Hein, Peter A. Fasching et autres

de, ch (code pays fourni par la source)

Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers

Lothar Häberle, Ramona Erber, Paul Gaß, Alexander Hein et autres

de (code pays fourni par la source)

Figure 1 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey et autres

Supplementary Figure S10 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey et autres

Supplementary Figure S5 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey et autres